The Australian software company Modeus is leveraging Imprivata’s biometric tech to strengthen the security of its HS8 electronic drug management platform. To that end, Modeus has integrated Imprivata’s Confirm ID prescription authentication platform into HS8, thereby allowing doctors to verify their identities and record drug activity with a fingerprint recognition scan or an ID card instead of a paper trail.
The HS8 platform is designed specifically for hospitals, and can provide comprehensive drug administration for all areas of the facility. The technology is intended to eliminate the need for paper records, while still enabling secure witness signing and reauthentication procedures for those receiving and distributing regulated medical substances.
“Digitising these workflows enables Imprivata and Modeus to provide a secure, audited trail of who did what, where, and when – witnessed by whom – as it relates to Schedule 8 medicines,” said Imprivata Chief Medical Officer Sean Kelly.
“The goal for HS8 was to improve clinical workflow efficiency whilst maintaining a highly secure system that provides full accountability and transparency. Our partnership with Imprivata allows that,” added Modeus CEO Carl Zufi. “Users will no longer be required to manually enter a username and password for each controlled drug register entry.”
Zufi went on to explain that the improved HS8 can be integrated into existing Imprivata infrastructure, and can run off of a touchscreen to facilitate more efficiency in busy areas of the hospital.
Earlier this year, Imprivata announced that the Confirm ID platform is now compatible with Google Chrome, and previously added online verification functionality through a collaboration with DigiCert. The company’s tech is compliant with the DEA’s requirements for the Electronic Prescribing of Controlled Substances.
Imprivata has also partnered with Microsoft to launch Healthcare Seamless SSO, a cloud-based identity and access management tool designed to make workflows more efficient in the healthcare industry.
November 22, 2019 – by Eric Weiss